Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Puma Biotechnology (PBYI)

Puma Biotechnology (PBYI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Puma Biotechnology 10880 WILSHIRE BOULEVARD SUITE 2150 LOS ANGELES CA 90024 USA

www.pumabiotechnology.com P: 424-248-6500 F: 424-248-6501

Description:

Puma Biotechnology, Inc. is a small cancer biotech whose only marketed product, Nerlynx (neratinib) was launched in the United Statesfor the treatment of early stage HER2-positive breast cancer in patients who have been previously treated with Roche's Herceptin-based adjuvant therapy. The drug was also approved in the European Union. Nerlynx in combination with Roche's Xeloda was approved'by the Food and Drug Administration for third-line HER2-positive metastatic breast cancer. Meanwhile, several additional studies on Nerlynx targeting different types of breast cancer patient populations as well as other types of cancers are currently underway. A key analysis of Nerlynx is the phase II SUMMIT basket study for treating solid tumors in patients with activating EGFR, HER2 or HER4 mutated cancers. Puma markets Nerlynx in the United States and has several sub-licenses in various regions outside the United States to commercialize Nerlynx in some international markets.

Key Statistics

Overview:

Market Capitalization, $K 123,492
Enterprise Value, $K 138,562
Shares Outstanding, K 48,239
Annual Sales, $ 235,640 K
Annual Net Income, $ 21,590 K
Last Quarter Sales, $ 47,080 K
Last Quarter Net Income, $ -4,530 K
EBIT, $ 18,910 K
EBITDA, $ 30,430 K
60-Month Beta 1.09
% of Insider Shareholders 23.70%
% of Institutional Shareholders 61.29%
Float, K 36,806
% Float 76.30%
Short Volume Ratio 0.47

Growth:

1-Year Return -14.09%
3-Year Return -62.46%
5-Year Return -77.06%
5-Year Revenue Growth -6.12%
5-Year Earnings Growth 115.05%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.05 on 08/01/24
Next Earnings Date 11/07/24
Earnings Per Share ttm 0.19
EPS Growth vs. Prev Qtr 10.00%
EPS Growth vs. Prev Year -280.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

PBYI Ratios

Ratio
Price/Earnings ttm 13.16
Price/Earnings forward 10.26
Price/Earnings to Growth N/A
Return-on-Equity % 18.36%
Return-on-Assets % 4.13%
Profit Margin % 9.16%
Debt/Equity 1.84
Price/Sales 0.52
Price/Cash Flow 3.73
Price/Book 2.63
Book Value/Share 0.99
Interest Coverage 2.70
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar